Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Pricing Reform Puts Cancer Drug Innovation At Risk, Drug Leaders Warn

Nov 02 2022

• By Jessica Merrill

Galien CEO Panel — Industry leaders discussed impacts of the IRA at the Galien Forum • Source: Galien

Related Content

Medicare Price ‘Negotiation’ Would Have Stymied Verzenio Advance In Early Cancer – Lilly’s Ricks

Jul 27 2022

Medicare Price Negotiation Savings Would Rise To $101Bn With Revisions To Legislation – CBO

Jul 13 2022

Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law

Aug 16 2022

President Bio-den? Executive Order Highlights Value Of Biotech – But Doesn’t Change Pricing Message

Sep 15 2022

Alkermes To Spin Out Oncology Business, Says Inflation Reduction Act Boosts Its Value

Nov 03 2022

Pharma Braces For Potential Landmark Moment For US Drug Price Controls

Aug 02 2022

Related Companies

Merck & Co., Inc.

Regeneron Pharmaceuticals, Inc.

Pfizer Inc.

Additional Topics

Innovation Legislation Pricing Debate Leadership Cancer BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.